Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation

Journal of Immunology

Volumn 163, Issue 9, 1999, Pages 5145-5156

  Truitt, Robert L ^a   Johnson, Bryon D ^a   Hanke, Carrie ^a   Talib, Sohel ^b   Hearst, John E ^b,c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CERUS CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSORALEN DERIVATIVE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ARTICLE; CELL FATE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DOSE RESPONSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTOCHEMISTRY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET A RADIATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELLS, CULTURED; CLONAL ANERGY; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FICUSIN; GRAFT VS HOST REACTION; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MICE, INBRED AKR; MICE, INBRED C57BL; PSORALENS; PUVA THERAPY; RADIATION CHIMERA; RADIATION-SENSITIZING AGENTS; RECEPTORS, INTERLEUKIN-2; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032711448     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Forman, S. J. 1998. Stem cell transplantation in acute leukemia. Curr. Opin. Oncol. 10:10.
2. Szydlo, R., J. M. Goldman, J. P. Klein, R. P. Gale, R. C. Ash, F. H. Bach, B. A. Bradley, J. T. Casper, N. Flomenberg, J. Gejewski, et al. 1997. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J. Clin. Oncol. 15:1767.
3. van Besien, K., K. A. Sobocinski, P. A. Rowlings, S. C. Murphy, J. O. Armitage, M. R. Bishop, O. K. Chaekal, R. P. Gale, J. P. Klein, H. M. Lazarus, et al. 1998. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 92: 1832.
4. Passweg, J. R., P. A. Rowlings, and M. M. Horowitz. 1998. Related donor bone marrow transplantation for chronic myelogenous leukemia. Hematol. Oncol. Clin. North Am. 12:81.
5. Horowitz, M. M., R. P. Gale, P. M. Sondel, J. M. Goldman, J. Kersey, H. J. Kolb, A. A. Rimm, O. Ruyden, C. Rozman, B. Speck, et al. 1990. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555.
6. Passweg, J. R., P. Tiberghien, J. Y. Cahn, M. R. Vowels, B. M. Camitta, R. P. Gale, R. H. Herzig, D. Hollzer, M. M. Horowitz, N. Ifrah, et al. 1998. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transpl. 21:153.
7. Truitt, R. L., and B. D. Johnson. 1995. Principles of graft-vs.-leukemia reactivity. Biol. Blood Marrow Transpl. 1:61.
8. Trigg, M. E. 1993. Bone marrow transplantation using alternative donors: mismatched related donors or closely matched unrelated donors. Am. J. Pediatr. Hematol. Oncol. 15:141.
9. Anasetti, C., R. Elzioni, E. W. Petersdorf, P. J. Martin, and J. A. Hansen. 1995. Marrow transplantation from unrelated volunteer donors. Annu. Rev. Med. 46: 169.
10. Davies, S. M., J. E. Wagner, D. J. Weisdorf, X. O. Shu, B. R. Blazar, H. Enright, P. B. McGlave, and N. K. Ramsay. 1996. Unrelated donor bone marrow transplantation for hematological malignancies-current status. Leuk. Lymphoma 23: 221.
11. Sullivan, K. M., P. L. Weiden, R. Storb, R. P. Witherspoon, A. Fefer, L. Fisher, C. Anasetti, F. R. Appelbaum, C. Batlgerd, et al. 1989. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 73:1720.
12. Goldman, J. M., R. P. Gale, M. M. Horowitz, J. C. Biggs, R. E. Chanplin, E. Gluckman, R. G. Hoffman, S. J. Jakobsen, A. M. Marmont, P. B. McGlave, et al. 1988. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T cell depletion. Ann. Intern. Med. 108:806.
13. Marmont, A. M., M. M. Horowitz, R. P. Gale, K. Sobocinski, R. C. Ash, D. W. van Bekkum, R. E. Champlin, K. A. Dicke, J. M. Goldman, R. A. Good, et al. 1991. T-cell depletion of HLA-identical transplants in leukemia. Blood 78:2120.
14. Hessner, M. J., D. J. Endean, J. T. Casper, M. M. Horowitz, C. A. Keever-Taylor, M. Roth, N. Flomenberg, and W. R. Drobyski. 1995. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia Blood 86:3987.
15. Kolb, H. J., J. Mittermüller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent CML in marrow transplant patients. Blood 76:2462.
16. Collins, R. H., Jr., O. Shpilberg, W. R. Drobyski, D. L. Porter, S. Giralt, R. Champlin, S. A. Goodman, S. N. Wolff, W. Hu, C. Verfaillie, et al. 1997. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:433.
17. Bonini, C., G. Ferrari, S. Verzeletti, P. Servida, E. Zappone, L. Ruggieri, M. Ponzani, S. Rossini, F. Mavilio, C. Traversari, C. Bordignon, et al. 1997. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276:1719.
18. Munshi, N. C., R. Govindarajan, R. Drake, L. M. Ding, R. Iyer, R. Saylors, J. Kornbluth, S. Marcus, Y. Chiang, D. Ennest, L. Kwak, C. Reynolds, G. Tricot, B. Barlogie, et al. 1997. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 89:1334.
19. Link, C. J., , R. K. Burt, A. E. Traynor, W. R. Drobyski, T. Seregina, J. P. Levy, L. Godon, S. T. Rosen, W. H. Burns, B. Camilla, et al. 1998. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction: HGTRI 0103. Hum. Gene Ther. 9:115.
20. Lin, L., D. N. Cook, G. P. Wiesehahn, R. Alfonso, B. Behrman, G. D. Cimino, L. Corten, F. B. Damonte, R. Dikeman, K. Dupuis, et al. 1997. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37:423.
21. Pathak, M. A., and T. B. Fitzpatrick. 1992. The evolution of photochemotherapy with psoralens and UVA (PUVA): 2000 BC to 1992 AD. J. Photochem. Photobiol. B 14:3.
22. Cimino, G. D., H. B. Gamper, S. T. Issacs, and J. E. Hearst. 1985. Psoralens as photoactive probes of nucleic acid structure and function: organic chemistry, photochemistry and biochemistry. Annu. Rev. Biochem. 54:1151.
23. Scherer, R., B. Kern, and O. Braun-Falco. 1977. The human peripheral lymphocyte: a model system for studying the combined effect of psoralen plus black light. Klin. Woschenschr. 55:137.
24. Morhenn, V. B., C. J. Benike, and E. G. Engleman. 1980. Inhibition of cell mediated immune responses by 8-methoxypsoralen and long-wave ultraviolet light: a possible explanation for the clinical effects of photoactivated psoralen. J. Invest. Dermatol. 75:249.
25. Laskin, J. D., F. H. Mermelstein, N. D. Heindel, and Y. Ron. 1993. Selective inactivation of lymphocytes after psoralen/ultraviolet light (PUVA) treatment without affecting systemic immune responses. J. Leukocyte. Biol. 54:138.
26. Kozenitzky, L., M. David, B. Sredai, M. Albeck, and B. Shohat. 1992. Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet A. Photochem. Photobiol. 9:24.
27. Johnson, R. L. Staiano-Coico, I. Cardinale, R. Nabeya-Tsukifuji, and J. G. Kueger. 1996. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem. Photobiol. 63:566.
28. Enomoto, D. N., P. T. Schellenkens, S. L. Yong, I. J. ten Berge, J. R. Mekkes, and J. D. Bos. 1997. Extracorporeal photochemotherapy (photopheresis) induces apoptosis in lymphocytes: a possible mechanism of action of PUVA therapy. Photochem. Photobiol. 65:177.
29. Mielke, V., G. Staib, and W. Sterry. 1995. Systemic treatment for cutaneous lymphomas. Recent Results Cancer Res. 139:403.
30. Perez, M., R. Edelson, L. Laroche, and C. Berger. 1989. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J. Invest. Dermatol. 9:669.
31. Berger, C. L., M. Perez, L. Laroche, and R. Edelson. 1990. Inhibition of autoimmune disease in a murine model of systemic lupus erylhematosus induced by exposure to syngeneic photoinactivated lymphocytes. J. Invest. Dermatol. 94:52.
32. Ullrich, S. E. 1991. Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimental murine graft-versus-host disease across major histocompatibility barriers. J. Invest. Dermatol. 96:303.
33. Grass, J. A., D. J. Hei, K. Metchette, G. D. Cimino, G. P. Wiesehahn, L. Corash, and L. Lin. 1998. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 91:2180.
34. Grass, J. A., T. Wafa, A. Reames, D. Wages, L. Corash, J. L. M. Ferrara, and L. Lin. 1999. Prevention of transfusion associated graft vs. host disease (TA-GVHD) by photochemical treatment. Blood 93:3140.
35. Wollowitz, S., S. T. Isaacs, H. Rapoport, H. P. Spielman (inventors), and Cerus Corp. (assignee). Compounds for the photodecontamination of pathogens in blood. U.S. Patent 5,399,719. March 21, 1995.
36. Truitt, R. L., C. Y. Shih, A. V. LeFever, L. D. Templis, M. Andreani, and M. M. Bortin. 1983. Characterization of alloimmunization-induced T-lymphocytes reactive against AKR leukemia in vitro and correlation with graft-versus-leukemia activity in vitro. J. Immunol. 131:2050.
37. Pechhold, K., T. Pohl, and D. Kabelitz. 1994. Rapid quantification of lymphocyte subsets in heterogeneous cell populations by flow cytometry. Cytometry 16:152.
38. Truitt, R. L., C. Hanke, J. Radke, R. Mueller, and J. T. Barbieri. 1998. Glycosphingolipids as novel targets for T-cell suppression by the B subunit of recombinant heat-labile enterotoxin. Infect. Immun. 66:1299.
39. Taswell, C. 1981. Limiting dilution assays for the determination of immunocompetent cell frequencies. J. Immunol. 126:1614.
40. Fontaine, P., and C. Perreault. 1990. Diagnosis of graft-versus-host disease in mice transplanted across minor histocompatibility barriers. Transplantation 49:1177.
41. Bortin, M. M., and R. L. Truitt. 1977. AKR T cell acute lymphoblastic leukemia: a model for human T cell leukemia-lymphoma. Biomedicine 26:309.
42. Schreiber, K. I., and J. Herman. 1993. The effect of chronic graft-versus-host disease on B cell development. Transplantation 55:597.
43. Johnson, B. J., E. E. Becker, and R. L. Truitt. 1999. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol. Blood Marrow Transpl. 5:123.
44. 2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. J. Immunol. 154:5542.
45. Truitt, R. L., B. J. Johnson, C. McCabe, and M. B. Weiler. 1997. Graft-versus-leukemia. In Graft-vs-Host Disease, 2nd Ed. J. L. M. Ferrara, H. J. Deeg, and S. A. Burakoff, eds. Marcel Dekker, New York, p. 385.
46. Talib, S., A. Reames, W. Liu, J. McLaughlin, J. Hanchett, B. Van Houton, and J. E. Hearst. 1999. Use of S-59/UVA-treated leukocytes for allogeneic cellular immunotherapy (ACIT). J Photochem. Photobiol. 69:19S.
47. Ash, R. C., J. T. Casper, C. R. Chitambar, R. Hansen, N. Bunin, R. L. Truitt, C. Lawton, K. Murray, J. Hunter, L. A. Baxter-Lowe, et al. 1990. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N. Engl. J. Med. 322:481.
48. Champlin, R., S. Giralt, D. Przepiorka, W. Ho, K. Lee, J. Gajewski, S. Netner, B. Andersson, R. Wallerstein, C. Ippolito, et al. 1992. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus-leukemia. Prog. Clin. Biol. Res. 377:385.
49. + cells. Immunology 94:101.
50. +, radiosensitive T cells of parental origin, oppose cells capable of down-regulating cytotoxicity in murine acute lethal graft-versus-host disease. Clin. Immunol. Immunopathol. 89:260.
51. Sykes, M., M. L. Romick, and D. H. Sachs. 1990. Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Natl. Acad. Sci. USA 87:5633.
52. Dey, B. R., Y. G. Yang, G. L. Szot, D. A. Pearson, and M. Sykes. 1998. Interleukin-12 inhibits graft-versus-host disease through a Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 91: 3315.
53. Pelszynski, M. M., G. Moroff, N. L. C. Luban, B. J. Taylor, and R. R. Quinones. 1994. Effect of γ irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion associated graft vs. host disease. Blood 83:1683.
54. Waller, E. K., I. Redei, A. M. Yeager, E. F. Winton, T. Heffner, C. D. Hillyer, R. Carter, K. Smith, H. K. Holland, G. Connaghan, et al. 1997.7.5 Gy irradiation attenuates the graft vs. host disease potential of allogeneic lymphocytes while preserving anti-leukemic activity in pre-clinical and clinical studies. Blood 90(Suppl. 1):547a.
55. Yee, C., S. R. Riddell, and P. D. Greenberg. 1997. Prospects for adoptive T cell therapy. Curr. Opin. Immunol. 9:702.
56. Rooney, C. M., H. E. Heslop, and M. K. Brenner. 1998. EBV specific CTL: a model for immune therapy. Vox Sang. 74(Suppl. 2):497.
57. Warren, E. H., M. Gavin, P. D. Greenberg, and S. R. Riddell. 1998. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation. Curr. Opin. Hematol. 5:429.